Navigation Links
Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine
Date:10/6/2011

tuzumab (Herceptin®).  Only 25% of breast cancer patients have HER-2 levels high enough to be eligible for Herceptin.

A controlled, randomized, and single-blinded Phase II clinical study of AE37 in HER-2 expressing breast cancer patients is currently underway to establish clinical efficacy.  The study endpoint is a reduction in cancer relapse after two years compared to patients not receiving AE37.  There are currently over 200 patients enrolled in the study with either node positive or high-risk node-negative breast cancer.  While positive preliminary results suggested that statistically definitive results could be obtained in 2012, the company opted to enroll an additional 100 patients in early 2011 to ensure sufficient patient numbers.  In particular, these additional patients are required to have low HER-2 expression levels such that they are not eligible for trastuzumab.  It is anticipated that a planned Phase 3 trial will be conducted in this specific patient population.

The many clinical trials conducted in the field of active immunotherapy of cancer over the last decade have provided increasing evidence that it is possible to engage the immune system to focus on and destroy cancer cells. Part of what has been learned over this time is the importance of specific activation of CD4+ T-helper cells in the generation of a robust and effective immune response. Equally clear is the validity of the HER2 protein as a target for cancer therapy. Importantly, HER2 is expressed at low to intermediate levels in a high percentage of breast as well as many other tumor types.  HER2 expression at these levels requires active immunotherapy, such as AE37, rather than passive immunotherapy such as Herceptin. For this reason, the company is continuing with plans for a Phase II prostate cancer study as well as other novel clinical applications of AE37 with interested parties.

"Antigen Express continues to make progress
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Antigen Express AE37 Cancer Vaccine Featured in Scientific American
2. Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
3. Generex Provides Update on Spinout of Antigen Express
4. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
5. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
6. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
7. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
8. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
9. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
10. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
11. Medicago succesfully expresses VLP antigen for A H1N1 strain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Proove Biosciences , ... excited to announce a new genetic test built upon ... Pain Perception Test will provide physicians with an ... pain tolerance levels are stratified between individuals. With this ... a person has a genetic predisposition that will affect ...
(Date:9/30/2014)... , September 30, 2014 ... intuitive browsing of chemistry in documents ... software solutions and consulting services for life science ... information and generate Markush structures from documents. ... organizations intellectual property, however generating and understanding Markush ...
(Date:9/30/2014)... BioHealth Innovation, Inc. (BHI), a ... and increasing access to early-stage funding in ... Tania Fernandez , Ph.D., has joined the BHI ... a member of the management team for a new ... million in seed and early-stage equity investments to therapeutics, ...
(Date:9/30/2014)... 2014 The custom stainless steel fabrication ... Show 2014. The Boston Area Chapter of ISPE (International ... day-long event for Wed., Oct. 1 at Gillette Stadium ... the largest in ISPE Boston’s long history, with more ... attendees expected. , HOLLOWAY AMERICA President David Simpson ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3
... SUNNYVALE, Calif., Sept. 26 Cepheid (Nasdaq:,CPHD) will ... Growth Stock,Conference on October 3, 2007 at 10:40 ... York. John R. Sluis, Cepheid,s Chief Financial Officer ... Officer, will provide,a corporate overview. The webcast, ...
... strategic platform for reducing risk of cancer ... drug development, ... ; MTAX) held its 2007 annual shareholders meeting,(Annual Meeting) on Tuesday, September ... a majority of CTI,s shares are,held by Italian shareholders. At the 2007 ...
... BioInformatics, SINGAPORE, Sept. 26 /Xinhua-PRNewswire/ -- ... Ltd, a leader in reconfigurable computing,applications headquartered ... The,BioIT Alliance is a cross-industry group working ... pace of drug discovery and realize the,potential ...
Cached Biology Technology:Cepheid to Present at William Blair Small-Cap Growth Stock Conference 2Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results 2Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results 3Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results 4Progeniq Joins Microsoft in Bio IT Alliance 2Progeniq Joins Microsoft in Bio IT Alliance 3
(Date:9/30/2014)... German . ... risky situations such as exposure to predators. Researchers from ... a long-term study on different populations of great tits ... ambient temperature. High metabolic rates and low temperatures were ... birds were more likely to approach potential predators. , ...
(Date:9/30/2014)... of perilous threats in today,s ocean. From overfishing ... fragile coral ecosystems are disappearing at unprecedented rates ... of corals surrounding the island of Moorea in ... tropical environment: coral guard-crabs. New research from the ... scientist Seabird McKeon and the museum,s predoctoral fellow ...
(Date:9/30/2014)... 30, 2014 Winners of The Economist,s prestigious ... scheduled to take place at the JW Marriott Hong Kong on ... winners will share their experiences and the lessons those hold for ... proven innovation over the past decade, will be presented at a ... the summit. It will be the first time the ceremony has ...
Breaking Biology News(10 mins):Risky metabolism 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... led by the Karolinska Institutet, Sweden and the University of ... and the composition of human gastrointestinal bacteria. In a study ... the team outline new evidence suggesting that the human genome ... billions of microbes in the human gastrointestinal tract collectively known ...
... senior author Morris J. Birnbaum, MD, PhD, the Willard ... for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, ... works in a different way than previously understood. Their ... hormone glucagon,s ability to generate an important signaling molecule, ...
... cells in all higher organisms cells need to bind to ... tissues. Mysteries have remained, however, about exactly how cells manage ... Scripps Research Institute (TSRI) have now solved part of this ... α-catenin, which is essential to this process. The ...
Cached Biology News:International study suggests human genes influence gut microbial composition 2Most-used diabetes drug works in different way than previously thought 2New study defines the long-sought structure of a protein necessary for cell-cell interaction 2
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... the yolk protein Vtg in plasma from juvenile ... biomarker for endocrine disrupting chemicals (EDCs) with estrogenic ... an accepted screening test for the estrogenic effects ... EIA kit is a double-antibody immunometric (sandwich) EIA ...
... sequence is from rat SCAMP 5. The sequence of this ... Q - P - Q - T - Q - Y ... Y - T - Y - S - N(233). ... the polyclonal antibody that reacts with this product and the rat ...
... Have a novel target for which no antibody ... made custom antibodies for a variety of pharmaceutical, ... happy to put our technology and expertise in ... Access to our patented RabMAb development technology , ...
Biology Products: